Regeneron stock falls 4.54 percent to USD 752.25 ahead of earnings

Published on 09/29/2026 at 09:20 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Regeneron stock fell to USD 752.25 on September 28, while HSBC lifted its target to USD 920.00. Q2 revenue rose 16.7 percent to USD 4.29 billion.

Fotorealistisches Biotech-Labor mit Forschern und Pipetten an sterilen Arbeitsplätzen — Regeneron Pharma US75886F1075 zeigt ein fotorealistisches Biotech-Labor mit Forschern bei sorgfältigen Pipettierarbeiten am sterilen Steriltisch, Illustration mit AI erstellt.

Regeneron stock (ISIN US75886F1075) fell 4.54 percent to USD 752.25 on Nasdaq on September 28, 2026, as the biotechnology company entered the final weeks before its next earnings report. The move leaves the shares below their 52-week high of USD 859.34 and above the 52-week low of USD 541.00.

HSBC raises its target

The latest analyst signal points in the opposite direction. According to MarketBeat on September 10, 2026, HSBC raised its Regeneron price target from USD 800.00 to USD 920.00 and maintained a Buy rating. MarketBeat also reported a Moderate Buy consensus and an average target of USD 802.18.

The gap between the latest market price and the HSBC target makes the analyst call a material counterpoint to the September 28 selloff. It also shows why the next operating update matters more than a single trading session for the stock's valuation.

Q2 delivered a clear earnings beat

Regeneron's most recent reported quarter supplied strong operating evidence. MarketBeat reported that Q2 2026 revenue reached USD 4.29 billion, up 16.7 percent from the same quarter a year earlier. Adjusted EPS came in at USD 14.29 versus a USD 10.16 consensus estimate, a USD 4.13 beat.

The underlying comparison is important because the earnings gain was not limited to sales growth. The latest quarter also exceeded the prior-year adjusted EPS figure of USD 12.81, while the revenue result surpassed the USD 3.82 billion analyst estimate cited by MarketBeat.

October 30 sets the next test

Regeneron has scheduled its Q3 2026 financial and operating results for October 30, 2026, according to the company investor page. The release date places the next major test beyond the September 28 price reaction and should give investors a fresh read on commercial execution and pipeline progress.

Regeneron stock last stood at USD 752.25 on Nasdaq on September 28, 2026, with a market capitalization of USD 77.5 billion and trading volume of 1,065,274 shares. The stock's position between its yearly low and high leaves the next earnings report as the clearest dated checkpoint.